ArticlePediatric research2025
Cytotoxic T-cell activation profile in critically ill children with malignancies and hemophagocytic lymphohistiocytosis.
Article in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe early identification of hemophagocytic lymphohistiocytosis (HLH) in critically ill children with malignancies is challenging. The value of an activated cytotoxic T-cell profile in diagnosing HLH in this group of patients is unknown.
methodsCritically ill children with malignancies who suffered from persistent cytopenia in the pediatric intensive care unit were included. Children were divided into two groups based on how many clinical HLH diagnostic criteria they fulfilled: M-HLH group, ≥5 criteria; hematologic malignancy (HM) group, ≤4 criteria. Flow cytometry tests were performed within 24 h after the patient's admission.
resultsThirty-seven children who fulfilled the requirements were enrolled. Twenty children were classified into the M-HLH group and 17 into the HM group. The M-HLH group exhibited a higher mortality rate than the HM group. CD38 + HLA-DR + CD8+ T cells% and interferon-gamma (IFN-γ) were elevated in the M-HLH group. The area under the curve values of the two indexes were 0.906 and 0.897 respectively for the identification of M-HLH in the critically ill children, with CD38+/HLA-DR + CD8+ T cells% > 39.66% and IFN-γ > 22.58 exhibiting the best performance.
conclusionCytotoxic T-cell activation profile with CD38 + HLA-DR + CD8+ T cells% and IFN-γ is valuable in the early diagnosis of HLH in critically ill children with malignancies. IMPACT: The early diagnosis of hemophagocytic lymphohistiocytosis in critically ill children with malignancies (M-HLH) remains a major challenge for intensivists. Cytotoxic T-cell activation profile with the frequency of CD38 + HLA-DR+ T cells in CD8+ T cells (CD38 + HLA-DR + CD8+ T cells%) and interferon-gamma (IFN-γ) is valuable in the early identification of pediatric M-HLH. These findings will support the future implementation of T-cell activation markers in the clinical management of children with M-HLH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.